These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 14722330

  • 21. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
    Williams PD, Anderson PS, Ball RG, Bock MG, Carroll L, Chiu SH, Clineschmidt BV, Culberson JC, Erb JM, Evans BE.
    J Med Chem; 1994 Mar 04; 37(5):565-71. PubMed ID: 8126695
    [Abstract] [Full Text] [Related]

  • 22. Effect of stimulatory and inhibitory drugs on uterine electrical activity measured noninvasively from the abdominal surface of pregnant rats.
    Buhimschi CS, Saade GR, Buhimschi IA, Gokdeniz R, Boyle MB, Garfield RE.
    Am J Obstet Gynecol; 2000 Jul 04; 183(1):68-75. PubMed ID: 10920311
    [Abstract] [Full Text] [Related]

  • 23. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
    Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, Graham SL, Vacca JP, Williams TM, Koblan KS, Kane SA.
    J Pharmacol Exp Ther; 2008 Feb 04; 324(2):416-21. PubMed ID: 18039958
    [Abstract] [Full Text] [Related]

  • 24. Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
    Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z.
    J Pharmacol Exp Ther; 2007 Mar 04; 320(3):1268-78. PubMed ID: 17170312
    [Abstract] [Full Text] [Related]

  • 25. The separate uterotonic and prostaglandin-releasing actions of oxytocin. Evidence and comparison with angiotensin and methacholine in the isolated rat uterus.
    Chan WY.
    J Pharmacol Exp Ther; 1980 Jun 04; 213(3):575-9. PubMed ID: 7205617
    [Abstract] [Full Text] [Related]

  • 26. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
    Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 2002 Mar 04; 300(3):1122-30. PubMed ID: 11861823
    [Abstract] [Full Text] [Related]

  • 27. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
    McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD.
    Am J Physiol Regul Integr Comp Physiol; 2007 Jul 04; 293(1):R299-305. PubMed ID: 17395790
    [Abstract] [Full Text] [Related]

  • 28. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Jul 04; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 29. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
    Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G.
    J Pharmacol Exp Ther; 2004 Sep 04; 310(3):905-14. PubMed ID: 15131245
    [Abstract] [Full Text] [Related]

  • 30. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
    Russell R, Doyle R, Turner J, Attkins N, Ramsey S, Weibley L, Bateman L, Bictash M, Neal-Morgan S, Ivarsson M, Pullen N.
    Eur J Pharmacol; 2011 Nov 30; 670(2-3):347-55. PubMed ID: 21958878
    [Abstract] [Full Text] [Related]

  • 31. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of premature labor in sheep by a combined treatment of nimesulide, a prostaglandin synthase type 2 inhibitor, and atosiban, an oxytocin receptor antagonist.
    Grigsby PL, Poore KR, Hirst JJ, Jenkin G.
    Am J Obstet Gynecol; 2000 Sep 22; 183(3):649-57. PubMed ID: 10992188
    [Abstract] [Full Text] [Related]

  • 33. Oxytocin (OT) action in uterine tissues of cyclic and early pregnant gilts: OT receptors concentration, prostaglandin F(2)alpha secretion, and phosphoinositide hydrolysis.
    Franczak A, Ciereszko R, Kotwica G.
    Anim Reprod Sci; 2005 Sep 22; 88(3-4):325-39. PubMed ID: 16143221
    [Abstract] [Full Text] [Related]

  • 34. Progesterone and mifepristone modify principally the responses of circular myometrium to oxytocin in preparturient rats: comparison with responses to acetylcholine and to calcium.
    el Alj A, Winer N, Lallaoui H, Delansorne R, Ferre F, Germain G.
    J Pharmacol Exp Ther; 1993 Jun 22; 265(3):1205-12. PubMed ID: 8510004
    [Abstract] [Full Text] [Related]

  • 35. Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366,682 and L-366,948.
    Clineschmidt BV, Pettibone DJ, Reiss DR, Lis EV, Haluska GJ, Novy MJ, Cook MJ, Cukierski MA, Kaufman MJ, Bock MG.
    J Pharmacol Exp Ther; 1991 Mar 22; 256(3):827-32. PubMed ID: 2005582
    [Abstract] [Full Text] [Related]

  • 36. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 22; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 37. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G.
    J Clin Invest; 1996 Dec 15; 98(12):2729-38. PubMed ID: 8981918
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
    Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T.
    J Med Chem; 2002 Jun 06; 45(12):2579-88. PubMed ID: 12036367
    [Abstract] [Full Text] [Related]

  • 39. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):224-32. PubMed ID: 18573246
    [Abstract] [Full Text] [Related]

  • 40. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
    Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H.
    J Pharmacol Exp Ther; 2007 Jun 20; 321(3):1144-53. PubMed ID: 17360958
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.